Real world evidence from a retrospective multi-center analysis for the combination immunotherapy ipilimumab and nivolumab as first-line treatment in advanced renal cell carcinoma

Materna L.,Schlack K., Stelmach R.,Zschäbitz S., Neuberger S., Aydogdu C., Casuscelli J., Egenolf T., Silberg M.,Steinestel J., Strauss A., Kirchhoff F., Ahrens M., Paffenholz P., Cathomas R., Gossler C., Ivanyi P., Rehlinghaus M., Hilser T., Grünwald V.

European Urology Open Science（2023）

引用 0|浏览2

暂无评分

关键词

advanced renal cell carcinoma,combination immunotherapy ipilimumab,nivolumab,multi-center,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要